Skip to main content
. 2020 Mar 12;111(4):1333–1343. doi: 10.1111/cas.14352

Table 1.

Characteristics of patients with multiple myeloma treated with lenalidomide and dexamethasone

Number of patients 48 (100)
Age (y)
Median (range) 69 (45‐84)
Sex
Male/female 19/29
M‐protein
IgG 21 (44)
IgA 11 (23)
BJP 11 (23)
IgD 4 (8)
Nonsecretory 1 (2)
Stage (ISS)
I 11 (23)
II 20 (42)
III 17 (35)
RT‐PCR and FISH
CCND1 15 (33)
t(11;14)+ 8 (53)
11 polysomy 3 (20)
NA 2 (13)
ND 2 (13)
FGFR3 11 (23)
t(4;14)+ 10 (91)
NA 1 (9)
c‐MAF 7 (15)
t(14;16)+ 5 (71)
NA 2 (29)
Triple negative a 11 (27)
ND 4 (8)
ASCT
+/− 14/34
Prior therapies
Median (range) 2 (1‐6)
Prior bortezomib therapy
+/− 43 (90)/5
Prior thalidomide therapy
+/− 11 (23)/37
Best response
CR 3 (6)
VGPR 5 (10)
PR 24 (50)
SD 13 (27)
PD 2 (4)
NE 1 (2)

Data are shown as n (%) unless otherwise indicated.

Abbreviations: ASCT, autologous stem cell transplantation; BJP, Bence Jones protein; CR, complete response; ISS, International Staging System; NA, no abnormality; ND, not done; NE, not evaluated; PD, progressive disease; PR, partial response; SD, stable disease; VGPR, very good partial response.

a

CCND1‐, FGFR3‐, c‐MAF‐negative in RT‐PCR.